Plural Concentric Cores Patents (Class 424/471)
  • Patent number: 10226430
    Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralized polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: March 12, 2019
    Assignee: TILLOTTS PHARMA AG
    Inventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
  • Patent number: 10098866
    Abstract: A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 16, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hajime Ishida, Makoto Fukuta
  • Patent number: 10098835
    Abstract: A multi-step method of making a mammalian subcutaneous medical implant or non-implant for releasing self-contained drugs on a controlled basis over at least a 3 day period includes depositing at least portions of one or more individual layers of the implant by at least one computer controlled 3-D printer. The 3-D printing method may be accomplished via an array of 3-D nozzles that deposit materials (such as plastics, thermoplastics, coating materials, drug-containing matrix materials, non-drug containing matrix materials, bonding materials, biodegradable materials and/or the like) in very small, precise portions. The materials may be deposited in liquid, powder, sheet or other forms. Non-implant forms may also be provided by the techniques disclosed herein.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: October 16, 2018
    Inventors: Robert W. Adams, Wayne C. Pollock
  • Patent number: 9730899
    Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 15, 2017
    Assignee: Evonik Roehm GmbH
    Inventors: Hans Bär, Thomas Fürst, Gerhard Renner, Michael Gottschalk
  • Patent number: 9616057
    Abstract: Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 11, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: William H. Robinson, Jeremy Sokolove, Qian Wang
  • Patent number: 9592203
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: March 14, 2017
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 9446009
    Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: September 20, 2016
    Assignee: Hallux, Inc.
    Inventors: Frank Kochinke, Corinne Bright
  • Patent number: 9404162
    Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria of the present invention are also provided.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: August 2, 2016
    Assignee: MARS, INCORPORATED
    Inventors: Thomas William-Maxwell Boileau, Barry Pius Kiely, Liam Diarmuid O'Mahony, John MacSharry, Greg Dean Sunvold
  • Patent number: 9339489
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: May 17, 2016
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Norman Coyle, Thomas G West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Patent number: 9333177
    Abstract: The present invention relates to a novel liquid delivery carrier comprising a specific grade of glyceryl caprylate and PEG-40 hydrogenated castor oil in particular amounts. This carrier can be loaded with slightly or poorly water soluble substances and filled into hard gelatin capsule shells for final administration to a subject. Also disclosed are filling compositions comprising such delivery carrier and hard gelatin capsules filled with the carrier and the composition of the invention. The delivery carrier of the invention proved to be compatible with both the hard gelatin capsule shells and the substances loaded into it.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: May 10, 2016
    Assignee: Capsugel Belgium NV
    Inventors: David Delmarre, Marie-Sophie Lina Martina, Jan Emiel Godelieve Vertommen
  • Patent number: 9283304
    Abstract: A biocompatible metallic material may be configured into any number of implantable medical devices, including intraluminal stents. The biocompatible metallic material may comprise a magnesium alloy. The magnesium alloy implantable medical device may be designed to degrade over a given period of time. In order to control the degradation time, the device may be coated or otherwise have affixed thereto one or more coatings, one of which comprises a material for controlling the degradation time and maintain a pH neutral environment proximate the device. Additionally, therapeutic agents may be incorporated into one or more of the coatings on the implantable medical device.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: March 15, 2016
    Assignee: CARDINAL HEALTH SWITZERLAND 515 GmbH
    Inventor: Jonathon Z. Zhao
  • Patent number: 9283192
    Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a prolonged manner at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping, shortly before waking and continues to administer the drug during the early waking hours. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a prolonged release of drug.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: March 15, 2016
    Assignee: UNIVERSITY OF STRATHCLYDE
    Inventors: Alexander Mullen, Howard Stevens, Sarah Eccleston
  • Patent number: 9248095
    Abstract: A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 2, 2016
    Assignee: Shaklee Corporation
    Inventors: Kuei-tu Chang, Carsten R. Smidt, John Castillo, William J. Mergens
  • Patent number: 9192177
    Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: November 24, 2015
    Assignee: The Iams Company
    Inventors: Thomas William-Maxwell Boileau, Barry Pius Kiely, Liam Diarmuid O'Mahony, John MacSharry, Greg Dean Sunvold
  • Patent number: 9173860
    Abstract: The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinaphthy, thalassemia and aplastic anemia.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: November 3, 2015
    Inventors: Susan Park Perrine, Douglas V. Faller
  • Patent number: 9107819
    Abstract: A controlled release pharmaceutical dosage form for controlled release of an active ingredient, includes an active ingredient coated by a polymeric mixture of: at least a water insoluble polymer; and at least an indigestible water-soluble oligosaccharide. The use and method of making the same are also described.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: August 18, 2015
    Assignee: ROQUETTE FRERES
    Inventors: Olaf Haeusler, Daniel Wils, Juergen Siepmann, Youness Karrout
  • Publication number: 20150125524
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Application
    Filed: October 16, 2014
    Publication date: May 7, 2015
    Applicant: Pozen Inc.
    Inventor: John R. PLACHETKA
  • Publication number: 20150079169
    Abstract: The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (PPI) and optionally with NSAIDs, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other. In addition, the invention also provides the delivery of clopidogrel and a PPI, and optionally aspirin, in a sequential (orderly) manner that would allow for the delivery and metabolism of clopidogrel first, followed by the PPI, and thereafter optionally aspirin. A particular mode of the invention involves the combination of clopidogrel with coformulated immediate release omeprazole+enteric coated aspirin.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 19, 2015
    Applicant: POZEN INC.
    Inventor: John R. Plachetka
  • Publication number: 20150072005
    Abstract: Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 12, 2015
    Inventor: Joseph P. Habboushe
  • Patent number: 8962022
    Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 24, 2015
    Assignee: Aptalis Pharmatech, Inc.
    Inventor: Gopi Venkatesh
  • Publication number: 20150010625
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Application
    Filed: September 24, 2014
    Publication date: January 8, 2015
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 8889187
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 18, 2014
    Assignee: Shionogi Inc.
    Inventors: Edward M Rudnic, James D Isbister, Donald J Treacy, Jr., Sandra E Wassink
  • Patent number: 8877247
    Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: November 4, 2014
    Assignee: Alpharma Pharmaceuticals LLC
    Inventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
  • Publication number: 20140212489
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Application
    Filed: April 3, 2014
    Publication date: July 31, 2014
    Applicant: Pozen Inc.
    Inventor: John R. PLACHETKA
  • Patent number: 8778397
    Abstract: A method of making a pharmaceutical composition containing tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used as an active ingredient in various types of immediate release and controlled release dosage forms, including tablets, capsules, and beads.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: July 15, 2014
    Assignee: Mylan, Inc.
    Inventors: David T. Rossi, Boyong Li, James Paul McCall
  • Patent number: 8765179
    Abstract: The invention relates to processes for coating a surface with a crosslinked polyelectrolytes multilayer film incorporating a protein, preferably a growth factor type protein. The invention also relates to crosslinked polyelectrolytes multilayer films obtained by this process, and a coated surface obtained therefrom.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: July 1, 2014
    Assignees: Institut Polytechnique de Grenoble, Universite Montpellier 2 Sciences et Techniques, Centre National de la Recherche Scientifique
    Inventors: Catherine Picart, Thomas Crouzier
  • Patent number: 8758817
    Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: June 24, 2014
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Isabel Anstett-Klein, Marc Schiller, Hartmut Ney, Manfred Hartmann, Sabine Schäfer-Preuss
  • Patent number: 8747820
    Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 10, 2014
    Assignee: Hallux, Inc.
    Inventors: Frank Kochinke, Corinne Bright
  • Publication number: 20140141080
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 22, 2014
    Applicant: Pozen Inc.
    Inventor: John R. PLACHETKA
  • Patent number: 8703192
    Abstract: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: April 22, 2014
    Assignee: Takeda GmbH
    Inventors: Isabel Anstett-Klein, Rango Dietrich, Hartmut Ney, Marc Schiller, Sabine Schaefer-Preuss, Manfred Hartmann
  • Patent number: 8703186
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: April 22, 2014
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Patent number: 8703191
    Abstract: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as with an enteric coating composition, to provide delayed release and/or to enhance stability of the active agent.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: April 22, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement
  • Publication number: 20140037723
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 6, 2014
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Publication number: 20140004189
    Abstract: Modified release pharmaceutical compositions of memantine or pharmaceutically acceptable salts thereof are described. The compositions of invention are stable, possess improved formulation characteristics and also provide extended therapeutically effective plasma levels over a twenty four hours period. Processes of making these compositions are also described.
    Type: Application
    Filed: January 25, 2012
    Publication date: January 2, 2014
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Sandhya Rajendra Shenoy, Imran Shakoor Ghogari, Vijaykumar Shivajrao Patil
  • Patent number: 8591870
    Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: November 26, 2013
    Assignee: Hallux, Inc.
    Inventors: Frank Kochinke, Corinne Bright
  • Patent number: 8535715
    Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: September 17, 2013
    Assignees: Bristol-Myers Squibb Company, AstraZeneca UK Limited
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
  • Publication number: 20130209561
    Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
    Type: Application
    Filed: February 21, 2013
    Publication date: August 15, 2013
    Applicant: Endo Pharmaceuticals Inc.
    Inventor: Endo Pharmaceuticals Inc.
  • Patent number: 8486452
    Abstract: A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: July 16, 2013
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: David T. Rossi, Boyong Li, James Paul McCall
  • Patent number: 8449911
    Abstract: Granule, fine particle or tablet of excellent leaching property, comprising a drug active ingredient in high content realized by forming a layer containing drug active ingredient on core particles through a combination of a method of dispersing and adhering an active ingredient while spraying or adding a binder with a method of spraying or adding a solution or suspension wherein an active ingredient and a binder are contained so as to effect adhesion. Further, there are provided a drug composition containing such a granule, fine particle or tablet and a process for producing the same.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: May 28, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuji Yoneyama, Hiroto Bando
  • Patent number: 8425933
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: April 23, 2013
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Publication number: 20130078304
    Abstract: The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and Zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein Zaleplon or a pharmaceutically acceptable salt thereof and Zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of Zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of Zolpidem or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 28, 2011
    Publication date: March 28, 2013
    Applicant: TAIWAN BIOTECH CO., LTD.
    Inventors: HSIEN-JEN HSIEH, KUO-HUA YANG, CHIH-SHENG YANG, YU-CHENG WEI, CHUNG-HSUAN LU
  • Patent number: 8372225
    Abstract: A method and apparatus for assembling a plurality of independently formed solid components is provided thereby forming a single delivery vehicle for a pharmaceutical or pharmaceutical-like product. The solid components can be held and fed to the apparatus via a plurality of magazines. Pusher rods and the like can be used for positioning each of the solid components. Where the components are connected via a bonding liquid, a sprayer is provided and compression pins or the like press the components with the bonding liquid together to form the final product. A rivet or other connection structure can also be used and driven through holes in each of the solid components to form the final product.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: February 12, 2013
    Assignee: Glaxo Group Limited
    Inventors: Thomas Bailey, Ronnie Benditt, Nigel Brewerton, Steven D. Finkelmeier, Robert Glinecke, Luigi Martini, Paul Simmons
  • Publication number: 20120282336
    Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
    Type: Application
    Filed: November 12, 2010
    Publication date: November 8, 2012
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
  • Patent number: 8182836
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: May 22, 2012
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Patent number: 8148393
    Abstract: A zolpidem tablet having modified release is designed as a tablet-in-tablet dosage form.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: April 3, 2012
    Assignee: Synthon BV
    Inventors: Frans van Dalen, Korinde Annemarie Jansen, Farid Abedin Dorkoosh
  • Patent number: 8137734
    Abstract: The present invention is directed to a method of preparing an extended release pharmaceutical composition comprising cyclobenzaprine, comprising coating inert particles with a cyclobenzaprine-containing a drug layering composition to form IR beads, then coating the IR beads with an extended-release coating to form ER beads.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: March 20, 2012
    Assignee: Aptalis Pharmatech, Inc.
    Inventors: Gopi M. Venkatesh, James M. Clevenger, Timothy Grinstead
  • Patent number: 8114435
    Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: February 14, 2012
    Assignee: AstraZeneca AB
    Inventors: Helene Depui, Per Lundberg
  • Patent number: 8105626
    Abstract: It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration which are prepared by using about 12% by weight or more (based on the total granules) of the acid-unstable chemical and blending a basic inorganic salt therewith to give granules of about 600 ?m or more in the average particle size.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: January 31, 2012
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshihiro Shimizu, Yoshinori Nakano
  • Patent number: 8092779
    Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: January 10, 2012
    Assignee: Rubicor Medical, LLC
    Inventors: Ary S. Chernomorsky, James W. Vetter, Simon Chernomorsky
  • Patent number: RE43799
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: November 13, 2012
    Assignee: Cosmo Technologies Limited
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati